[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Melbourne Health\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":104},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100340829","phase-4-posaconazole-pharmacokinetics-in-patients-receiving-chemotherapy-or-stem-cell-transplants-100340829",false,"NCT03717623","Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants","Pharmacokinetics Study of Posaconazole in Haematology Patients Receiving Standard of Care Treatment With Oral Posaconazole Prophylaxis for Invasive Fungal Infection","POPULAR","Inclusion Criteria:\n\n* Adult (≥18 years old) haematology patients receiving Posaconazole prophylaxis in the inpatient setting as standard of care.\n* Able to give informed consent.\n\nExclusion Criteria:\n\n* Unable to give informed consent.","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The purpose of the study is to investigate the pharmacokinetics of oral dosage of Posaconazole which is routinely administered as a standard care prophylaxis for patients undergoing cancer treatments.",[27,28,29,30,31,32,33],"Posaconazole","Pharmacokinetics","Invasive Candidiases","Invasive Aspergillosis","Invasive Mycosis","Fungal Infection","Prophylaxis","RECRUITING","2025-02-26",{"date":37,"type":38},"2025-02-28","ACTUAL",{"date":40,"type":38},"2019-08-01",{"date":42,"type":21},"2025-12-30",{"name":44,"class":45},"Melbourne Health","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":46},"100562761","phase-1-rescuing-bone-marrow-function-in-patients-with-aplastic-anaemia-and-bone-marrow-failure-post-allogeneic-transplantation-2-100562761","NCT06607367","REscuing Bone Marrow Function in Patients with AplaStic AnaEmia and Bone Marrow FaiLure Post AllogEneiC Transplantation 2","RESELECT2","Inclusion Criteria:\n\nPatient must meet ALL of the following:\n\n1. Poor Graft function OR Relapsed\u002Frefractory AA\n\n   1. Poor Graft Function defined as follows:≥95% donor chimerism at last reading OR ≥95% CD3 negative chimerism; ≥2 Lineage cytopenias defined as:\n\n      Thrombocytopenia:\n      * 30x109 \u002FL from D40-D60 OR\n      * 50 x10 9\u002FL from D60 onwards; Neutropenia requiring filgrastim support at any time post D40; Hb less than 80g\u002FL;\n   2. Relapsed \u002FRefractory AA defined as: Relapse after stem cell transplant OR relapsed post\u002Frefractory to 1st line immunosuppression without an unrelated donor identified.\n2. Age ≥18\n3. ECOG performance status 0-1\n4. Life expectancy greater than 6 months\n5. Patient's written informed consent\n\nExclusion Criteria:\n\n1. Active Grade 3-4 acute GVHD\n2. Relapsed or progressive disease on screening bone marrow biopsy or most recent PET imaging.\n3. Active second malignancy currently requiring treatment\n4. Human Immuno-deficiency Virus (HIV) infection.\n5. Any coexisting medical or psychological condition that would preclude participation in the required study procedures.\n6. Female patients who are both lactating and breast-feeding or have a positive serum pregnancy test during the screening period or a positive pregnancy test on Day 1 before first dose of study drug",{"count":55,"type":21},20,[57,58],"PHASE1","PHASE2","Allogeneic stem cell transplantation involves the transplanting of donor blood stem cells into a recipient, this is performed mainly for the treatment of blood cancers. The bone marrow is the organ that produces all blood cells and allogeneic stem cell transplantation results in the replacement of abnormal recipient bone marrow with donor blood cells as well as the production of donor immune cells from the donor bone marrow. The production of donor immune cells will hopefully lead to an immune response directed at any persisting cancerous cells leading to their eradication. As such, one of the key measures of success of a transplant is establishment of donor engraftment.\n\nEngraftment is considered successful when the patient has normal blood cell counts on routine laboratory testing as well as confirmation that the blood cells are being produced by donor bone marrow cells. Confirming donor blood cell production is done by a process called chimerism. Poor graft function (PGF) is a complication of allogeneic stem cell transplantation related to engraftment, manifested by low blood counts despite complete donor chimerism. This has significant consequences for the patient leaving them susceptible to infection because of low white blood cells and bleeding because of low platelets (the cell components that are important for blood clotting). There is currently no established treatment for this condition and patients with this condition who do not recover have a poor survival.\n\nAplastic anaemia (AA) is a rare autoimmune condition that results in a patient's own immune system attacking important components of their bone marrow resulting in low blood counts. The current treatments for AA include suppressing the immune system or a bone marrow transplant, however long term survival for patients who do not respond to these treatments or relapse is poor and more effective treatments are required.\n\nThere is emerging evidence that demonstrates that the components of the immune system are dysfunctional and result in excessive immune activation resulting in suppression of the bone marrow characteristic of PGF. Similar features of immune dysfunction has been demonstrated in AA. Ruxolitinib is a drug that may be able to reduce this excessive immune activation. Eltrombopag is a drug that has been shown to stimulate the production of blood cells. The aim of this study is to evaluate whether the combination of ruxolitinib and eltrombopag is safe and effective in the treatment of PGF and AA.",[61,62],"Poor Graft Function","Aplastic Anemia Idiopathic","NOT_YET_RECRUITING","2024-09-18",{"date":66,"type":38},"2024-09-23",{"date":68,"type":21},"2024-10-30",{"date":70,"type":21},"2026-10-30",{"name":44,"class":45},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":80,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":84,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},"100537548","national-robotics-assisted-radical-prostatectomy-database-100537548","NCT06279260","National Robotics-Assisted Radical Prostatectomy Database","National Robotics-Assisted Radical Prostatectomy Database: Exploring Learning Curves and Long Term Surgical, Oncological and Patient Reported Outcome Measures (PROMS)","RASOR","Inclusion Criteria:\n\nTo be eligible to participate in this database, an individual must meet all of the following criteria:\n\n1. Individuals who consent to participate,\n2. within the age range of 18 to 90 years,\n3. confirmed diagnosis of localized prostate cancer (PCa)\n4. patients receiving medical attention at hospitals engaged in collaborative efforts with the designated database.\n\nExclusion Criteria:\n\n1. Participants are not eligible to take part in the database:\n2. Individuals who have not undergone robotic surgery for prostatectomy or TP biopsy. ,\n3. without a diagnosis of prostate cancer or\n4. who decline to provide consent for the collection of their health information\n5. Under the age of 18 years.","MALE","90 Years",{"count":83,"type":21},10000,"5 Years","OBSERVATIONAL","In Australia, nearly 70 men are diagnosed with Prostate cancer every day. Prostate removal (Radical Prostatectomy) is the proven treatment option to control cancer spread. Most of the prostate removal surgeries are done using robots. Robotic assisted prostate removal surgeries have been invented to minimise the risk of side effects post-surgery. Doctors prefer the robots over open surgery as there are benefits to patients (shorter hospital stays, lesser blood loss and better quality of life) and surgeons (better dexterity, improved field of vision and less pain). However, the cost of the robot outweighs the benefits at present and there is very less information concerning the long-term outcomes for patients.\n\nStudies conducted so far are small scale studies and the results from these studies cannot be generalized to the population at large in Australia. So, there is need for a largescale study that will look at the long-term outcomes and the factors that impact robotic surgeries across the metropolitan and rural hospital sectors.\n\nHence, this comprehensive database has been setup to collaborate with major hospitals, across metropolitan and rural areas in Australia. Through this database, researchers will be able to explore the diagnostic pathway for Prostate cancer and understand the long-term benefits of robotic surgery through patient reported questionnaires. Outcomes from this database will also help compare the quality of care against other powerhouses of robotic surgery.\n\nEventually, the database aims to standardize diagnostic pathways and clinical notes that are the same across different hospitals conducting robotic-assisted surgeries for Prostatectomy and improve care for prostate cancer patients across the country.",[88,89,90,91,92,93,94],"Database","Prostate Cancer","Robotic-assisted Radical Prostatectomy","Surgical Outcomes","Oncological Outcomes","Patient Reported Outcome Measures","Learning Curve","2024-08-22",{"date":97,"type":38},"2024-08-26",{"date":99,"type":38},"2024-07-01",{"date":101,"type":21},"2050-12",{"name":44,"class":45},8,""]